Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL

NCT05093140 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Primary Extranodal Lymphoma
DLBCL

Interventions

DRUG: Camrelizumab

Sponsor

Sun Yat-sen University

Collaborators

[object Object]